Fruquintinib (Fruzaqla) sold under the brand name 爱优特 in china, is an oral, highly selective, small molecule VEGF receptor inhibitor. Because of the kinase selectivity of Fruzaqla, the risk of off-target toxicity is less than the risk with multikinase inhibitors, including regorafenib.
Chinese Version
Brand name：Fruzaqla (爱优特)
INN name：Fruquintinib (呋喹替尼胶囊)
Manufacturer：HUTCHMED (和黄医药)
Packaging：1mg*7capsules/Box
Packaging：5mg*7capsules/Box
Inquire&E-mail: care@100pei.com
November 9, 2023, The FDA has approved fruquintinib (Fruzaqla) to treat adults with metastatic colorectal cancer who received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and an anti-EGFR therapy for cases that are RAS wild-type and medically appropriate.
扫一扫 
